Larimar Therapeutics
LRMR
93 hedge funds and large institutions have $880M invested in Larimar Therapeutics in 2015 Q1 according to their latest regulatory filings, with 44 funds opening new positions, 32 increasing their positions, 12 reducing their positions, and 9 closing their positions.
389% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 9
167% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 12
83% more capital invested
Capital invested by funds: $481M → $880M (+$398M)
60% more funds holding
Funds holding: 58 → 93 (+35)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| 1 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
+$119M |
| 2 |
DM
Deerfield Management
New York
|
+$41.5M |
| 3 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$31.2M |
| 4 |
Jennison Associates
New York
|
+$26.2M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$21.1M |
Top Sellers
| 1 |
TRV
Third Rock Ventures
Boston,
Massachusetts
|
-$55.4M |
| 2 |
PA
Perceptive Advisors
New York
|
-$8.58M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$3.81M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.22M |
| 5 |
Principal Financial Group
Des Moines,
Iowa
|
-$1.63M |
LRMR Hedge Fund Activity: Q1 2015 in Review
93 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q1 2015, worth a combined $880M — up 83% from $481M a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new LRMR positions and 9 closed out — a net gain of 35 holders — while 32 added to existing stakes and 12 trimmed.
The largest buyer was Foresite Capital Management II, adding an estimated $119M. The largest seller was Third Rock Ventures, cutting an estimated $55.4M.
- 93 institutional investors held Larimar Therapeutics (LRMR) as of Q1 2015, up from 58 in Q4 2014.
- Funds reported $880M of Larimar Therapeutics stock for Q1 2015, up 83% quarter-over-quarter.
- 44 funds opened new Larimar Therapeutics positions in Q1 2015 and 9 closed out, a net change of +35 holders.
- The largest Larimar Therapeutics buyer in Q1 2015 was Foresite Capital Management II, an estimated $119M added.
- The largest Larimar Therapeutics seller in Q1 2015 was Third Rock Ventures, an estimated $55.4M sold.
Based on aggregated 13F filings for Q1 2015.